PharmiWeb1h
ICON portfolio of AI tools drives clinical trial efficiencies
ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced ...
PharmiWeb59m
RYSTIGGO® (rozanolixizumab), for generalized myasthenia gravis (gMG), receives EU approval for two new administration methods
UCB, a global biopharmaceutical company, today announced the CHMP (Committee for Medicinal Products for Human Use) has issued a positive opinion for the self-administration of RYSTIGGO® ...
PharmiWeb1h
Aston Institute for Membrane Excellence receives £500,000 grant from the Wolfson Foundation for state-of-the-art microscope
Aston Institute for Membrane Excellence (AIME) has received a £500,000 grant from the Wolfson Foundation to purchase an ultrafast confocal spinning disc microscope. This instrument will accelerate ...
PharmiWeb1h
BrightHeart Unveils Breakthrough AI Results at the…
BrightHeart, a global leader in artificial intelligence (AI) solutions for obstetrics and pediatric cardiology, presented two groundbreaking studies during the oral plenary and concurrent sessions on ...
PharmiWeb1h
Amicus Therapeutics launches Amicus Ignite, a proactive community funding programme for initiatives that support people living with Pompe disease
Amicus Therapeutics UK Limited (Nasdaq: FOLD), a patient-dedicated biotechnology company, today announced the launch of Amicus Ignite, a proactive community funding programme to support initiatives ...
PharmiWeb1h
Sarclisa is the first anti-CD38 treatment approved…
The National Medical Products Administration (NMPA) in China has approved Sarclisa, in combination with a standard-of-care regimen, bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment ...
PharmiWeb1h
Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR™ (sotatercept-csrk) Early and Move to Final Analysis
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the Phase 3 HYPERION study evaluating WINREVAIR (sotatercept-csrk) versus placebo (both in combination with ...
PharmiWeb1h
European Commission authorises ViiV Healthcare’s long-acting injectable Vocabria + Rekambys for HIV treatment in adolescents
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced that the European Commission has authorised Vocabria (cabotegravir ...
PharmiWeb1h
Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant
The National Medical Products Administration (NMPA) in China has approved Sarclisa, in combination with a standard-of-care regimen, bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment ...
PharmiWeb1h
Abbott Showcases Latest Research and Technology to Advance Care for Chronic Pain Conditions at NANS
Abbott announced new four-year data showing the long-term and sustained relief that its proprietary BurstDR™ spinal cord stimulation (SCS) technology provides people with chronic pain, particularly ...
PharmiWeb13h
MCS to Attend the 40th MD&M West Expo from February 4 to 6, 2025
BELLINGHAM, WASHINGTON / ACCESS Newswire / January 30, 2025 / As Medical Component Specialists strive to maintain its ...
PharmiWeb18h
Dental Burs Market to Reach USD 312.6 Million by 2034, Growing at a CAGR of 6.9%
Global Dental Burs MarketThe global dental burs market is projected to grow at a steady CAGR of 6.9%, reaching an estimated ...